MediciNova

MediciNova is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. “Over the past quarter, we…

MediciNova announced that it will be given a U.S. patent covering the use of ibudilast (MN-166) in treating eye disease. This oral medication aims to lessen inflammation, including that of progressive multiple sclerosis (MS). Specifically, it will cover ibudilast’s use in  treating injury or damage to the macula —…

People with primary progressive MS (PPMS) appeared to show a much stronger response and to be the” driving” force behind a slowing in brain atrophy seen with ibudilast treatment in the SPRINT‐MS trial, a post-hoc study analysis reports. The treatment response observed in brain atrophy was more evident…

A non-invasive retina imaging technique known as optical coherence tomography (OCT) provided evidence of the neuroprotective effect of ibudilast (MN-166) — an oral medication designed to reduce the body’s inflammatory responses —  in people with progressive forms of multiple sclerosis (MS). The data also…

Genentech‘s Ocrevus (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosis (SPMS) among U.S. neurologists, even though Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) were approved in March to treat this same MS…

A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses, or those whose disease is not active, MediciNova announced. Data from this single Phase 3 study may be used to request…

Treatment with oral ibudilast slows brain shrinkage in patients with primary progressive multiple sclerosis (PPMS), but not in those with secondary progressive MS (SPMS), according to results of a Phase 2b clinical trial. According to the findings, this could be partially due to faster disease progression in untreated…

Progressive multiple sclerosis patients — with primary or secondary progressive disease — treated with high doses of oral ibudilast in a Phase 2 clinical trial showed a 48 percent slowing in the progression of brain atrophy, or shrinkage, relative to those given a placebo, study data show. What this…

Top-line results from a clinical trial evaluating the investigational oral therapy ibudilast for progressive multiple sclerosis (MS) show that the therapy led to a significant reduction of brain atrophy in patients when compared to controls. Robert Naismith, MD, one of the study’s principal researchers from Washington University in St. Louis,…

The Japanese company MediciNova‘s anti-inflammatory agent ibudilast slows multiple sclerosis patients’ brain shrinkage and their loss of the protective myelin coating around nerve cells, a Phase 2 clinical trial shows. Robert J. Fox of Ohio’s Cleveland Clinic Neurological Institute presented the results at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, Oct. 25-28.

MediciNova will present data from its clinical trial of ibudilast (MN-166) in progressive multiple sclerosis (MS) at the upcoming 7th Joint ECTRIMS – ACTRIMS Meeting in Paris. The European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS) selected the presentation “…

Ibudilast (MN-166) has shown enough promise as a treatment for progressive multiple sclerosis (MS) that its U.S. Phase 2b trial (NCT01982942) should continue, the U.S. National Institute of Health’s Data and Safety Monitoring Board has recommended. A key goal of the 96-week trial is to determine whether ibudilast can slow the…

MediciNova, Inc., announced that MN-166 (ibudilast) has been approved for “fast track” development by the U.S. Food and Drug Administration (FDA) as a potential treatment for progressive multiple sclerosis (MS). Progressive MS includes both the primary progressive (PPMS) and secondary progressive (SPMS) forms of the disease. MediciNova’s MN-166 was licensed from Kyorin Pharmaceuticals for its potential…

MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…

MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of their ongoing clinical study evaluating ibudilast (MN-166) for the treatment of progressive…

MediciNova, Inc., has announced the acceptance of an abstract describing their ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS). The poster is to be presented at the American Academy of Neurology (AAN) 67th Annual Meeting, April 18 – 25, 2015 in Washington, DC. The presentation is titled…

MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in progressive multiple sclerosis patients. As of September 15th, 150 of an expected 250 patients have enrolled for treatment, and the trial is on track to complete enrollment by the…